Melphalan drug delivery system - Delcath Systems

Drug Profile

Melphalan drug delivery system - Delcath Systems

Alternative Names: CS-PHP-Melphalan; Delcath Hepatic CHEMOSAT Delivery System for Melphalan; Generation Two CHEMOSAT Delivery System for Melphalan; Melblez Kit; Melphalan/HDS; Melphalan/Hepatic Delivery System

Latest Information Update: 27 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University School of Medicine
  • Developer Delcath Systems
  • Class Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Neuroendocrine tumours; Malignant melanoma; Cholangiocarcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Liver metastases
  • Phase II Cholangiocarcinoma; Hepatocellular carcinoma

Most Recent Events

  • 27 Mar 2017 Delcath Systems plans a phase II/III registrational trial for Cholangiocarcinoma in USA
  • 21 Feb 2017 Retrospective efficacy and adverse events data from a clinical trial in Liver metastases released by Delcath Systems
  • 13 Sep 2016 Phase-III clinical trials in Liver metastases in Germany, Austria (Intrahepatic) (NCT02678572)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top